NCT00439465 · REGISTRY CONDITION SEARCH

Adoptive Cellular Immunotherapy Following Autologous Peripheral Blood Stem Cell Transplantation for Multiple Myeloma

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase: PHASE2
Status at capture: COMPLETED
Registry last update: 2019-03-26

The purpose of this study is to determine whether the administration of highly effective "killer" cells (cytotoxic T cells), along with Interleukin-2 (IL-2) and Recombinant Human Granulocyte Colony Stimulating Factor (GM-CSF) immediately following Autologous Peripheral Blood Stem Cell Transplantation (APBSCT) will enhance anti-tumor immune reconstitution and improve outcome of Multiple Myeloma patients. The overall hypothesis of this proposal is that immediately following APBSCT the immune reconstitution is optimal to administer "killer" cells, combined with the administration of IL-2 and GM-CSF.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Number of Participants With Adverse Events in All Subjects

→

outcome · POSTED

Count of Participants With Increased CD3+CD8+, CD8+ and CD56+ Concentrations Between Day 15 Post-Transplant and Days 21 to 28 Post-transplant

→

outcome · POSTED

Time to Recovery of Absolute Neutrophil Count

→

outcome · POSTED

Time to Recovery of Platelet Count

→

outcome · POSTED

Assessment of Disease Response to Treatment

→

outcome · POSTED

Number of Participants With Increased Expression of DAP10 and NKG2D on the CD8 Cell Population

→

outcome · POSTED

Determine the Methods of Tumor Cell Killing of the in Vivo CD8+ Cells: Cytotoxicity Assays, Blocking Experiments, Analysis of T-cell Receptor (TCR)

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→

Who could take part

eligibility Criteria: Inclusion Criteria: Multiple Myeloma: * Patients must meet criteria for diagnosis of Multiple Myeloma. * Patient must meet either criterion listed below: * Stage I, II, or III newly diagnosed multiple myeloma * Progressive or relapsed disease in partial response (PR) or complete response (CR) * Primary refractory disease. * Relapsed refractory disease. * Patients may have received a prior autologous transplant. * The patients must have recovered from all serious and life threatening effects of previous treatment at the time of study entry (unless this abnormality is believed to be due to the underlying myeloma). * The patient must have adequate bone marrow function, i.e. a total white blood cell count (WBC) of \> 2,000/ul, a Hemoglobin (Hgb) of \> 7 gm/dl, and a platelet count of \> 50,000/ul, unless this abnormality is believed to be due to the underlying myeloma. * The patient must have adequate liver function, i.e. bilirubin \<2.0 mg/dl, aspartate aminotransferase (SGOT), alanine aminotransferase (SGPT) not greater than 2 times the upper normal limit (unless this abnormality is believed to be due to the underlying myeloma). * The patient must have adequate renal function, i.e. serum creatinine \< 3.0 mg/dl, and/or creatinine clearance \>50 ml/min. This eligibility criterion is excluded if renal insufficiency is believed to be secondary to myeloma. * Age \>18 years and \< 75 years old * The patient must have a Karnofsky status \> 80% * Patients must have a life expectancy of at least 12 weeks * Left ventricular ejection fraction of \> 45% by radionuclide scan or echocardiography * Pulmonary function tests: forced vital capacity, Diffusing capacity of the lungs for carbon monoxide (DLCO) and expiratory volume in one second (FEV1) must be \> 50% of predicted * No significant co-morbid medical or psychiatric illness which would significantly compromise the patient's clinical care and chances of survival. * Informed written consent must be obtained. Patients must be able to give informed consent as a prerequisite to this procedure. The Informed Consent form will become part of his/her permanent record and a copy will be given to the patient Exclusion Criteria: * Medical, social, or psychological factors which would prevent the patient from receiving or cooperating with the full course of therapy. * Evidence on physical exam, lumbar puncture, computed tomography (CT), or magnetic resonance imaging (MRI) scan of central nervous system (CNS) involvement with malignancy * Any clinically significant cardiac disease (angina, myocardial infarction, congestive heart failure, ventricular arrhythmias requiring therapy) or clinically significant obstructive/restrictive pulmonary disease * Serology positive for human immunodeficiency virus (HIV) or human T-lymphotropic virus (HTLVI) * Active hepatitis B or C * History of seizures * Concurrent or expected need for therapy with corticosteroids * Active connective tissue disease * Current "clinically significant" pleural effusion, pericardial effusion, or ascites * Positive pregnancy test or presence of lactation * Collection of fewer than 1 x 106 cluster of differentiation 34 positive (CD34+) cells/kg (peripheral blood stem cells). If the apheresis collection is inadequate based on this criteria, the patient will be removed from protocol and a marrow harvest may be performed * A history of a second malignancy (other then squamous cell/ basal cell carcinoma of the skin or cervical dysplasia) must be reviewed by the Principal Investigator, before inclusion or exclusion in the study. Based upon the PI's review, this patient may be eligible (i.e., distant past history of a malignancy)
healthy Volunteers: false
maximum Age: 75 Years
minimum Age: 18 Years
sex: ALL
std Ages: ADULT
OLDER_ADULT

Treatment arms and interventions

arm Groups

description
Infusing IL-2 and GM-CSF post-Hematopoietic Stem Cell Transplant (HSCT)
intervention Names
Biological: Ex-vivo expanded effector cells
label
Ex-vivo expanded effector cells
type
OTHER

interventions

arm Group Labels
Ex-vivo expanded effector cells
description
This trial will test if the combination of infusing ex vivo expanded cytotoxic effector cells with IL-2 and GM-CSF post-transplant will accelerate immune reconstitution, resulting in an effector cell-versus-myeloma effect and, possibly, improved clinical outcomes.
name
Ex-vivo expanded effector cells
type
BIOLOGICAL

Study design

allocation

intervention Model

SINGLE_GROUP

masking Info

masking: NONE

primary Purpose

TREATMENT

Enrollment

count: 23
type: ACTUAL

Registered outcome plans (not posted results)

primary Outcomes

description
To establish the safety (toxicity) of myeloma patients treated with high dose melphalan, autologous peripheral blood stem cell transplantation (APBSCT) \& adoptive transfer of cytotoxic effector cells with Interleukin-2 (IL-2) and Recombinant Human Granulocyte Colony Stimulating Factor (GM-CSF).
measure
Number of Participants With Adverse Events in All Subjects
time Frame
From initiation of treatment on protocol until Day 100

secondary Outcomes

description
To demonstrate that the effector cell infusions result in a clinical effect, phenotypic analyses of blood samples using flow cytometry will be performed prior to, and after each infusion, focusing on the CD8 + populations (CD3+CD8+, CD8+CD56+). As a complement to flow cytometry, the following assays will be used to identify cell subset precursor frequencies, subset proliferation, and cytokine production: * Dye Dilution Proliferation Assay (DDPA) 36 - Evaluation of CD8+ T Cell Precursors * ELISPOT-Quantifying cytokine producing T cells:
measure
Count of Participants With Increased CD3+CD8+, CD8+ and CD56+ Concentrations Between Day 15 Post-Transplant and Days 21 to 28 Post-transplant
time Frame
Day 15 post-transplant and between days 21 to 28 post-transplant
description
To establish the time to engraftment of myeloma patients treated with high dose melphalan, APBSCT\& adoptive transfer of cytotoxic effector cells with IL-2 and GM-CSF.
measure
Time to Recovery of Absolute Neutrophil Count
time Frame
From initiation of treatment on protocol until Day 100
description
To establish the time to engraftment of myeloma patients treated with high dose melphalan, APBSCT\& adoptive transfer of cytotoxic effector cells with IL-2 and GM-CSF.
measure
Time to Recovery of Platelet Count
time Frame
From initiation of treatment on protocol until Day 100
description
To establish the disease response of myeloma patients treated with high dose melphalan, APBSCT\& adoptive transfer of cytotoxic effector cells with IL-2 and GM-CSF.
measure
Assessment of Disease Response to Treatment
time Frame
From initiation of treatment on protocol until Day 100
description
* Isolate CD3+CD8+ and CD8+CD56+ from patients' blood following transplant. * Identify NKG2D and DAP10 expression. * Determine the mechanism of tumor cell killing and the relationship to NKG2D or DAP 10 expression. After isolating CD8+ cells from patient's blood samples using the AutoMACS, we will evaluate the expression of NKG2D and DAP10 on all CD8+ cells (CD3+CD8+ and CD8+CD56+cells) pre-transplant (Baseline) and following the third and fourth cellular infusions using phenotypic analysis. We postulate the increased expression of both DAP10 and NKG2D on the CD8 population immediately following APSCT and effector cell infusions when compared to baseline.
measure
Number of Participants With Increased Expression of DAP10 and NKG2D on the CD8 Cell Population
time Frame
Pre-transplant and following the third and fourth cellular infusions
description
We will isolate the CD8+ populations (CD3+CD8+, CD8+CD56+) using the Auto MACS (Miltenyi) and then identify the mechanisms of tumor cell killing by the CD8+ cells obtained pre-transplant (Baseline) and following the third and fourth cellular infusions. We will examine mechanisms of tumor cell killing through NKG2D receptor, major histocompatibility complex (MHC) Class I molecules or through the T cell receptor. We postulate the CD8+ cells obtained from patient's blood will kill tumor cells both via MHC Class I and through the NKG2D receptor.
measure
Determine the Methods of Tumor Cell Killing of the in Vivo CD8+ Cells: Cytotoxicity Assays, Blocking Experiments, Analysis of T-cell Receptor (TCR)
time Frame
Pre-transplant and following the third and fourth cellular infusions.

Full study description

brief Summary: The purpose of this study is to determine whether the administration of highly effective "killer" cells (cytotoxic T cells), along with Interleukin-2 (IL-2) and Recombinant Human Granulocyte Colony Stimulating Factor (GM-CSF) immediately following Autologous Peripheral Blood Stem Cell Transplantation (APBSCT) will enhance anti-tumor immune reconstitution and improve outcome of Multiple Myeloma patients. The overall hypothesis of this proposal is that immediately following APBSCT the immune reconstitution is optimal to administer "killer" cells, combined with the administration of IL-2 and GM-CSF.

Source references

Source notices and limitations

Discovery and provenance

release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-75ba23909bcc5aee6677
requested nct id
NCT00439465
primary nct id
NCT00439465
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Plasma+Cell+Neoplasms&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
source record id
Source null
source file sha256
2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
payload sha256
a3c1603b65df5cff932d3784ef98e9820d93c979d0a240cf8eb9d7968324372b
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-75ba23909bcc5aee6677
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT00439465
occurrences
context exact
NCT00439465
end
11
exact text
NCT00439465
start
0
offset unit
unicode_code_points
query cond
Plasma Cell Neoplasms
query disease state id
ds-plasma-cell-neoplasms
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-plasma-cell-neoplasms-000.json
source file sha256
2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
source json pointer
/studies/6/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
63a5ba4a5cbe5d7adb7fa3d2433593a23c4b774738e17d83a25a0e4ebef2462d
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Plasma+Cell+Neoplasms&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true

Preserved source evidence · Not medical advice